Enniatin A as a Novel Hsp90 Machine Inhibitor Combining Cancer Cell Toxicity and Immunotherapy

Description:

AU researchers have developed a unique high throughput screen (HTS) based on the progesterone receptor (PR) and the five components of the Hsp90 machine. During their preliminary screening of natural products , they discovered that the cyclic peptide Enniatin A (EnnA) kills cancer cells through inhibition of the Hsp90 machine without a significant induction of HSR. In addition, EnnA induces a powerful T cell-mediated immune response, resulting in highly efficient tumor killing in a syngeneic mouse model and long-term memory against the primary tumor. At the molecular level, EnnA reduces the protein levels of two key mediators of tumor-induced immune tolerance: programmed cell death ligand-1 (PDL-1) and indolamine 2,3 dioxygenase (IDO).

Patent Information:
Category(s):
Therapeutics
For Information, Contact:
Carl Clark
Director Technology Transfer
Augusta University
caclark@augusta.edu
Inventors:
Ahmed Chadli
Keywords:
© 2018. All Rights Reserved. Powered by Inteum